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ABSTRACT
Background
Sequence analysis of the regulators of complement activation (RCA) cluster of genes at
chromosome position 1q32 shows evidence of several large genomic duplications. These
duplications have resulted in a high degree of sequence identity between the gene for factor H
(CFH) and the genes for the five factor H-related proteins (CFHL1–5; aliases CFHR1–5). CFH
mutations have been described in association with atypical haemolytic uraemic syndrome
(aHUS). The majority of the mutations are missense changes that cluster in the C-terminal
region and impair the ability of factor H to regulate surface-bound C3b. Some have arisen as a
result of gene conversion between CFH and CFHL1. In this study we tested the hypothesis that
nonallelic homologous recombination between low-copy repeats in the RCA cluster could
result in the formation of a hybrid CFH/CFHL1 gene that predisposes to the development of
aHUS.
Methods and Findings
In a family with many cases of aHUS that segregate with the RCA cluster we used cDNA
analysis, gene sequencing, and Southern blotting to show that affected individuals carry a
heterozygous CFH/CFHL1 hybrid gene in which exons 1–21 are derived from CFH and exons 22/
23 from CFHL1. This hybrid encodes a protein product identical to a functionally significant CFH
mutant (c.3572C.T, S1191L and c.3590T.C, V1197A) that has been previously described in
association with aHUS.
Conclusions
CFH mutation screening is recommended in all aHUS patients prior to renal transplantation
because of the high risk of disease recurrence post-transplant in those known to have a CFH
mutation. Because of our finding it will be necessary to implement additional screening
strategies that will detect a hybrid CFH/CFHL1 gene.
The Editors’ Summary of this article follows the references.
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Atypical HUS (aHUS) is characterised by the triad of a
microangiopathic haemolytic anaemia (Coombs’ test nega-
tive), thrombocytopenia, and acute renal failure in the
absence of a preceding diarrhoeal illness. aHUS can be either
sporadic or, if more than one member of a family is affected,
familial. In 1998 we established linkage in three families with
atypical haemolytic uraemic syndrome (aHUS) to a 26 cM
region at chromosome location 1q32 [1]. This area contains a
group of genes that play a pivotal role in the regulation of
complement activation (the regulators of complement acti-
vation [RCA] cluster). In one of these families we found a
mutation in the gene encoding the soluble regulator comple-
ment factor H [1] and subsequently in another we found a
mutation in the gene encoding membrane cofactor protein, a
transmembrane regulator [2]. In the third family extensive
screening of genes within the RCA cluster failed to reveal an
abnormality.
Complement genes within the RCA cluster are arranged in
tandem within two groups [3]. In a centromeric 360 kb
segment lie the genes encoding factor H (CFH) and ﬁve factor
H-related proteins—CFHL1–5 (aliases CFHR1–5) (Figure 1A).
Sequence analysis of this region shows evidence of several
large genomic duplications, also known as low copy repeats
(LCRs), resulting in a high degree of sequence identity
between CFH and the genes for the ﬁve factor H-related
proteins [4,5]. The secreted protein products of these genes
are similar in that they consist of repetitive units (;60 amino
acids) named short consensus repeats (SCRs) or complement
control protein modules. Each SCR is generally encoded by a
single exon. CFH consists of 20 SCRs and CFHL1 consists of
ﬁve. The highest degree of sequence identity is seen between
SCRs 18 and 20 of CFH and SCRs 3 and 5 of CFHL1. CFH
SCR 18 and CFHL1 SCR 3 consist of 59 amino acids. At the
nucleotide level the exons encoding these two SCRs differ by
ﬁve bases. Three result in an amino acid difference. CFH has
tyrosine, valine, and glutamine residues at positions 1,058,
1,060, and 1,076, respectively (encoded by triplets TAT, GTG,
and CAA), whilst CFHL1 has histidine, leucine, and glutamic
acid residues at positions 157, 159, and 175 (encoded by
triplets CAT, CTG and GAA). CFH SCR 19 and CFHL1 SCR 4
consist of 61 amino acids. The exons encoding these two SCRs
differ at one nucleotide position, which does not result in a
coding change. CFH SCR20 and CFHL1 SCR 5 consist of 67
amino acids. The exons differ at two nucleotide positions,
both of which affect the amino acid sequence of the encoded
proteins; CFH has serine and valine residues at positions
1,191 and 1,197 (encoded by triplets TCG and GTT) while
CFHL1 has leucine and alanine residues at positions 290 and
296 (encoded by triplets TTG and GCT). Mutations reported
in association with aHUS include c.3572C.T, which results in
the change S1191L and c.3590T.C, which results in V1197A,
either singly or in combination [6–8]. This raised the
possibility that gene conversion of CFH SCR 20 by SCR 5 of
CFHL1 is the mutational mechanism in a proportion of cases.
c.3226C.G, Q1076E has also been reported [6,9], raising the
possibility of gene conversion of CFH SCR 18 by SCR 3 of
CFHL1.
We recently reported two aHUS cases in which S1191L and
V1197A changes occurred in combination as de novo events
[10], thus providing unambiguous evidence that gene
conversion is the mutational mechanism involved. LCRs such
as those seen in the RCA cluster not only predispose to gene
conversion events but are also associated with genomic
rearrangements [11]. These rearrangements usually result
from nonallelic homologous recombination between LCRs. If
nonallelic recombination should occur between the dupli-
cated segments B and B9 shown in Figure 1B, a variety of
products are possible (Figure 1C and 1D). If recombination
occurred after the terminal exons of CFH and CFHL1
deletion of CFHL1 and CFHL3 would result. If recombination
occurred within the region containing the three terminal
exons (and their ﬂanking introns) of CFH and CFHL1, then
not only would CFHL3 be deleted, but a hybrid CFH/CFHL1
gene would be formed. If, for example, the recombination
occurred at ‘‘X’’ in Figure 1B, a hybrid gene would result that
consisted of the ﬁrst 21 exons of CFH (encoding SCRs 1–18 of
the hybrid gene) and the last two exons of CFHL1 (encoding
SCRs 19 and 20 of the hybrid gene) (Figure 1C). The hybrid
gene would encode a protein product identical to the
aforementioned S1191L/V1197A mutant, a change that we
have shown to be functionally signiﬁcant [10]. If the
recombination occurred at Y, CFHL3 and CFHL1 would be
deleted, but CFH would remain intact (Figure 1C). The
recombination event would also potentially lead to duplica-
Figure 1. Genomic Structure of the Region of the RCA Cluster Containing
the Genes Encoding Factor H and the Five factor H-Related Proteins
Genomic duplications including the different exons of the six genes were
originally determined by Male et al. [4] and are colour-coded. Exons are
indicated as vertical lines.
(A) Position of the genes encoding factor H and the factor H-related
proteins in a centromeric segment of the RCA cluster at 1q32.
(B and C) Nonhomologous recombination occurring at X would result in
a hybrid gene consisting of the first 21 exons of CFH (encoding SCRs 1–
18 of the hybrid gene) and the last 2 exons of CFHL1 (encoding SCRs 19
and 20 of the hybrid gene). If the recombination occurred at Y this would
result in deletion of CFHL3 and CFHL1 but CFH would remain intact.
(D) The recombination event would also potentially lead to a duplication
of CFHL1 and CFHL3.
(Figure adapted from Figure 1 of [15] with kind permission of Human
Mutation C 2006, Wiley Liss Inc., A Wiley Company.)
DOI: 10.1371/journal.pmed.0030431.g001
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Hybrid Complement Gene and Atypical HUStion of CFHL1 and CFHL3 (Figure 1D). There is already
evidence that nonallelic recombination leading to deletion of
CFHL1 occurs as a common polymorphism in the general
population [12], and we here show that this phenomenon also
leads to the formation of a hybrid CFH/CFHL1 gene
associated with aHUS. In particular, we have shown the
presence of such a hybrid gene in the affected members of
the remaining unsolved family from our original linkage
study [1].
Methods
Clinical Details and Informed Consent
The family that is the subject of our study was ﬁrst reported
in 1975 [13] and more recently in 1998 [1]. This is the
aforementioned one remaining unsolved family from our
original linkage study in three aHUS families in 1998 [1]. The
current pedigree is shown in Figure 2. Affected member I:2
died at the age of 57 y, 7 d after presenting with pericarditis,
heart failure, and hypertension.
II:1 presented with the classical features of HUS at the age
of 45 y, following a 9 mo history of hypertension. Serum
complement levels were normal. Renal function did not
recover and haemodialysis was commenced. Bilateral neph-
rectomy was undertaken because of ongoing haemolysis and
severe hypertension. He subsequently received two renal
transplants, one at the age of 46 y and the other at 49 y. Both
kidneys were lost to ‘‘acute rejection,’’ the ﬁrst after 18 mo
and the second after 8 mo. In retrospect the clinical and
histopathological features were compatible with recurrent
HUS. He died of a myocardial infarct at the age of 55 y.
II:2, the twin brother of II:1, presented at the age of 46 y
with acute renal failure and hypertension. Investigations were
compatible with a diagnosis of HUS. As with his brother,
bilateral nephrectomy was necessary to control ongoing
haemolysis and hypertension. He subsequently received two
transplants, one at the age of 47 y and the other at 60 y. Both
kidneys were lost within weeks of transplantation due to
recurrent HUS. II:7 and II:10 both died of acute renal failure.
II:8 died at the age of 82 y without any evidence of renal
disease.
III:3 is currently aged 53 y and is well. Complement proﬁles
have shown a persistently borderline low C3. III:4 presented
at the age of 19 y with a grand mal convulsion. She had
started an oral contraceptive 6 wk previously. Investigations
were consistent with HUS. A complement proﬁle was said to
be normal. She died 8 wk after presentation following cardiac
arrest. III:5 presented with HUS at the age of 5 y and died 6 d
after presentation. III:6 presented at the age of 28 y with a
short history of headaches and lethargy. Investigations were
compatible with a diagnosis of HUS. He has remained on
haemodialysis since then and is currently well. III:8 presented
at the age of 7 y with ﬂuid retention, hypertension, and acute
renal failure. He died 9 d after admission.
IV:1 presented at the age of 7 y with HUS following a viral
illness. Despite treatment with peritoneal dialysis, plasma
exchange, and prostacyclin, he did not recover renal
function. He received a cadaver renal transplant at age 16
y, which, despite daily plasma exchange, was lost to recurrent
HUS within the ﬁrst two postoperative weeks. He was
subsequently treated with both peritoneal dialysis and
haemodialysis. He died suddenly at the age of 22 y.
Figure 2. Pedigree of the Family
DOI: 10.1371/journal.pmed.0030431.g002
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Hybrid Complement Gene and Atypical HUSFigure 3. cDNA Evidence of a Hybrid Gene
(A) Inverted CFH exons 20–23 cDNA sequence showing the site of the first-round forward primers (blue), the second round forward primers (green), and
the reverse primers for both rounds (red). The nucleotides at which the CFH and CFHL1 sequences differ are shown in bold and highlighted (excluding
exon 20).
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Hybrid Complement Gene and Atypical HUSMutation screening of the genes for factor H, membrane
cofactor protein, and factor I in this family had not revealed
any abnormalities.
The study was approved by the Northern and Yorkshire
Multi-Centre Research Ethics Committee and informed
consent obtained.
Complement Assays
Convalescent EDTA plasma samples were obtained and
stored at  80 8C. C3 and C4 levels were measured by rate
nephelometry (Beckman Array 360; Beckman, Fullerton,
California, United States). Factor H levels were measured by
radioimmunodiffusion (Binding Site, Birmingham, UK).
CFH Genomic DNA Sequencing
CFH gDNA sequencing was undertaken as previously
described [6] apart from exon 23, where the primers used
were: forward 59-CCTAATTCTCATACATTAAACATCG-39
and reverse 59-CAACCGTTAGTTTTCCAGGA-39. All primers
incorporated a 59 ‘‘UNISEQ’’ M13-derived 17 bp tail that
allowed subsequent sequencing using a common forward (59-
GTAGCGCGACGGCCAGT-39) and reverse (59-CAGGGCG-
CAGCGATGAC-39) primer. PCR products were puriﬁed
using magnetic microparticles (AMPure, Beckman) to remove
unincorporated dNTPs, primers, and salts. Sequencing
reactions were carried out by dye terminator cycle sequenc-
ing (DTCS kit, Beckman) using UNISEQ primers, puriﬁed
using magnetic microparticles (CleanSeq, Beckman), and
electrophoresed on a ﬂuorescent 16 capillary sequencer
(Beckman CEQ 8000).
The reference nucleotide sequence for CFH was taken from
GenBank RefSeq (http://www.ncbi.nlm.nih.gov/RefSeq/) ﬁle
NM_000186.1, and the nucleotide numbering uses the A of
the ATG translation initiation start site as nucleotideþ1. The
factor H amino acid numbering includes the 18-residue signal
peptide. The reference nucleotide sequence for CFHL1 was
taken from Genbank RefSeq ﬁle NM_002113.1, and the
nucleotide numbering uses the A of the ATG translation
initiation start site as nucleotide þ1. CFH exons have been
numbered 1–23 according to Rodriguez de Cordoba et al.
[14]. In this nomenclature, exon 10 contributes to the
transcript for factor H-like protein 1 but not factor H. The
factor H-related protein 1 amino acid numbering includes
the 18-residue signal peptide.
CFH cDNA Sequencing
For cDNA sequencing of CFH (Figure 3) mRNA was
extracted from peripheral blood lymphocytes of family
members (affected and unaffected) and unrelated controls.
cDNA was prepared in a standard manner and CFH exons 21–
23 ampliﬁed by seminested PCR. The forward primers were
designed to be speciﬁc for CFH and were therefore sited in
exon 20, which is not homologous to CFHL1. The reverse
primer was complementary to both exon 23 of CFH and exon
6o fCFHL1 (Figure 3A). The ﬁrst-round forward primer was
59-GCCATACCCATGGGAGAGAAGA-39 and the second-
round forward primer was 59-CGGGTGAGCAAGTGACTTA-
CACT-39. The reverse primer for both rounds was 59-
GGATACTCCAGTTTCCCATCCCA-39. Each primer incor-
porated a ‘‘UNISEQ’’ tail as before to enable sequencing with
UNISEQ primers.
Identification and Screening of the Breakpoint in CFH/
CFHL1 Hybrid Gene
To identify and screen the breakpoint (Figure 4), ﬁrst we
ampliﬁed genomic DNA across the intron between exons 21
and 22 (CFHL1 exon 5) of the CFH/CFHL1 hybrid gene using
primers speciﬁc for CFH (forward) and CFHL1 (reverse)
sequence.
Next, we screened the identiﬁed breakpoint in the affected
family using the primer pair 59-CCATCTGGTGAGAGAG-
TACGTT-39 (forward) and 59-ACCCAGGACTATGTGCTCG-
GACT-39 (reverse) (Figure 4B), which anneal to both CFH and
CFHL1. Each primer incorporated a ‘‘UNISEQ’’ tail as before
to enable sequencing with UNISEQ primers.
CFH Dosage Analysis by Quantitative Fluorescent PCR
Two multiplex PCR assays were designed to simultaneously
amplify exons 20–23 of CFH. PCRs were carried out in 25 ll
volumes using 150 ng of DNA and contained 0.5 mM each
dNTP, 6.7 mM MgCl2, 12.5 pmol of each primer, 1 U of a hot
start Taq polymerase (Immolase, Bioline) in a buffer of 16
mM (NH4)2SO4, 67 mM Tris-HCl, 0.01% Tween-20. PCR
cycling conditions were such that ampliﬁcation remained in
the linear phase of the reaction (958C for 7 min; 20 cycles of:
(B) Inverted cDNA sequence of CFH exons 20–23 from III:6 (affected family member) showing evidence for a hybrid CFH/CFHL1 gene. Positions at which
the CFH and CFHL1 sequences differ are indicated by arrows. At the three differences in exons 22 and 23 (numbered 1–3) there is a heterozygous base
change, one allele being wild-type CFH and the other the equivalent base from CFHL1.
(C) Inverted cDNA sequence showing hybrid CFH/CFHL1 sequence (c.3590T.C, V1197A, and c.3572C.T, S1191L) in III:6 (affected) and III:3 (unaffected
carrier) compared to normal CFH sequence in III:1 (unaffected), III:7 (unaffected), and a normal unrelated control.
DOI: 10.1371/journal.pmed.0030431.g003
Table 1. Primer Sequences for the CFH QF-PCR Dosage Analysis
Exon Forward Reverse Basepairs
CFH exon 20 GAAACAGATTGTCTCAGTTTACCT GCTGGTCTCGAACTCCTGACCT 308
CFH exon 21 CTAGGTGGAACCACTTCTTTTTTTTCTAT GGAAGAATTGAATTTTAAGCACCATCAG 354
CFH exon 22 TTTCTTCCAGGACTCATTTCTTTC CTGTGAGTATTTTGTTACAAACAGTG 407
CFH exon 23 GATGTTTCTACATAGTTGGTTTGGAT AGTTCTGAATAAAGGTGTGCAC 379
MLH1 exon 14 TGTCTCTAGTTCTGGTGCCTGGTG CTACCTCATGCTGCTCTCCTTAGC 298
BRCA1 exon 16 AATTCTTAACAGAGACCAGAAC AAAACTCTTTCCAGAATGTTGT 450
DOI: 10.1371/journal.pmed.0030431.t001
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Hybrid Complement Gene and Atypical HUSFigure 4. Identifying and Screening the Break-
point Region
(A) Sequence of unique PCR product generated
with specific CFH (forward) and CFHL1 (reverse)
primers from III:6 (affected) demonstrating the
hybrid product. Unique CFH positions are
indicated with black arrows, and unique CFHL1
nucleotides are indicated with red arrows.
(B) The genomic sequence of CFH is shown
aligned above CFHL1. Exons 21 and 4 of the two
genes respectively are highlighted in grey. The
primer-binding sites for the PCR are shown in
red. The differences visible in intron 21/4 from
sequencing the product are highlighted in the
standard base colours A (green), C (blue), G
(black), and T (red). The breakpoint is within the
region underlined.
(C) Sequence of the intron between exons 21
and 22 shows a switch from heterozygosity at
CFH/CFHL1 unique bases to a CFHL1 sequence in
III:3 (unaffected carrier) and III:6 (affected)
compared with III:1 (unaffected), III:7 (unaf-
fected), and a normal unrelated control.
DOI: 10.1371/journal.pmed.0030431.g004
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Hybrid Complement Gene and Atypical HUS94 8C for 45 s, 60 8C for 45 s, 72 8C for 1 min; and a ﬁnal
extension of 10 min at 72 8C). Primers that amplify MLH1
exon 14 and BRCA1 exon 16 were included in the assay as
controls for normal dosage. One of each pair of primers was
ﬂuorescently labelled (59FAM), and all primers are shown in
Table 1. After PCR ampliﬁcation products were analysed by
capillary electrophoresis (ABI, Perkin Elmer). Peak areas were
obtained for each sample and dosage quotients calculated.
CFH Multiplex Ligation-Dependent Probe Amplification
The multiplex ligation-dependent probe ampliﬁcation
(MLPA) reaction has been described [15]. In this study a
completely synthetic probe set was used, obviating the need
for a cloning step in the production of probes. Probes were
designed to determine dosage for a range of CFH exons, along
with control probes for MSH2 exon 1 and MLH1 exon 19
(NM_000251, NM_000249). Each probe pair hybridises to
immediately adjacent targets at the sequence of interest.
Hybridisation sequences are shown in Figure 5 and Table 2.
Probe pairs also contained binding sites for primers used in
the MLPA reaction, as well as stuffer sequence to ensure that
each ampliﬁed probe product is of a unique length.
Oligonucleotides were obtained from TAG Newcastle Limited
(Gateshead, UK [now available at VH Bio: http://www.vhbio.
com/home.aspx]). 59 probes were RP-column puriﬁed. 39
probes were 59-phosphorylated and puriﬁed by desalting.
Reagents for the MLPA reaction were purchased from
MRC-Holland (Amsterdam, the Netherlands). The ligation
reactions were carried out according to the manufacturer’s
recommended protocol using 100–200 ng of genomic DNA
and 2 fmol of probe. Incubations and PCR ampliﬁcations
were carried out on a DNA Engine Tetrad 2 thermal cycler
(BioRad Laboratories, Hercules, California, United States).
Ampliﬁed products were diluted 1 in 10 to give peak heights
within the quantitative range (approximately 100–4,000 units)
on the ABI PRISM 3130 Genetic Analyzer capillary electro-
phoresis system (Applied Biosystems, Foster City, California,
United States). For size standards, 1 ll of diluted product and
0.5 ll of ROX 500 internal size standard were made up to 10
ll using dH2O, and samples were run on the ABI 3130. Peak
areas for each sample were determined using the proprietary
Genemapper software and dosage quotients calculated.
Southern Blots
To provide further conﬁrmation that the point of
recombination responsible for the CFH/CFHL1 hybrid gene
lies within the intron between CFH exons 21/22 and CFHL1
exons 4/5, Southern blots were done using a 1.1 kb probe
(Figure 6). The putative crossover leading to the formation of
the CFH/CFHL1 hybrid gene is shown as a line that crosses
over 110–150 bases into the introns between exons 21/22 of
CFH and 4/5 of CFHL1. A DNA probe was prepared by PCR
ampliﬁcation of a 1.1 kb region spanning the putative
breakpoint using the following primers: forward, 59-
GTAGCGCGACGGCCAGTGGTCTATCAGTGTTCTAGC-
GAAGGA-39 and reverse, 59-GTGCACCAGTTAACAGGC-
CAT-39.
Genomic DNA (10 lg) from two affected individuals, one
unaffected individual, and two individuals who were homo-
zygously deleted for CFHL1 was digested with HindIII.
Electrophoresis was carried out overnight in a 0.8% agarose
gel in 13 TAE buffer (0.04 M Tris-acetate buffer, 0.001 M
EDTA) at 40 mA. DNA was transferred to a nylon membrane
(Hybond Nþ, Amersham [http://www.amersham.com/]) after
denaturation in 1.5 M NaCl, 0.5 M NaOH and neutralisation
in 0.4 M Tris base, 0.25 M trisodium citrate, 2.5 M NaCl. The
DNA probe (20 ng) was labelled using the Rediprime system
(Amersham). Hybridisations were carried out overnight at 65
8C in a mix containing 53 SSC (0.75 M NaCl, 0.075 M
trisodium citrate), 53 Denhardt’s (0.1% PVP, 0.1% BSA, and
0.1% Ficoll), 0.1% SDS, 0.1% sodium pyrophosphate, 10%
dextran sulfate, and 100 lg/ml sonicated denatured salmon
sperm DNA. The ﬁlter was washed at 65 8C to a ﬁnal
stringency of 0.53 SSC (including 0.1% SDS) and autoradio-
graphed with intensifying screens for 12 h.
Results
Complement Profiles
Serum levels of C3, C4, and factor H are shown in Table 3.
Factor H levels were normal in all family members, as was
expected, because the secreted product of the hybrid gene is
identical to the factor H mutant c.3572C.T, S1191L/
c.3590T.C, V1197A.
CFH gDNA Sequencing
Sequencing of genomic CFH DNA from II:8 (unaffected
carrier), III:1 (unaffected), III:3 (unaffected carrier), III:6
(affected), III:7 (unaffected) and IV:1 (affected) showed wild-
type sequence. This was expected, because the hybrid CFH/
CFHL1 gene described here would not be picked up by
genomic sequencing using CFH-speciﬁc primers
CFH cDNA Sequencing
In III:3 (unaffected carrier) and III:6 (affected), cDNA
sequencing showed two heterozygous changes c.3572C.T
and c.3590T.C in exon 23, leading to S1191L and V1197A,
respectively (Figure 3B and 3C). In addition, there was a
heterozygous synonymous change in exon 22. These changes
were not found in III:1, III:7 (both unaffected), or an
unrelated control.
Identification and Screening of the Breakpoint in the CFH/
CFHL1 Hybrid Gene
The DNA breakpoint in III:6 (affected) was identiﬁed by
sequencing PCR products using speciﬁc CFH (forward) and
CFHL1 (reverse) primers spanning the intron between exons
21 and 22 (CFHL1 exon 5) of the CFH/CFHL1 hybrid gene.
This generated a unique product, sequencing of which
Table 2. Hybridisation Sequences for the CFH Exons 22/23 MLPA
Probes
Probe Name Hybridisation Sequence
CFH_ex22 59 TTAATATTCACGTGGCTGGAAAAATCTC
CFH_ex22 39 TGTGATGAGTCTGATATTTCACTGTTTG
CFH_ex23 59 GGACAGCCAAACAGAAGCTTTATTC
CFH_ex23 39 GAGAACAGGTGAATCAGTTGAATTTGTG
MSH2_ex1 59 GCTTCGTGCGCTTCTTTCAGGGCA
MSH2_ex1 39 TGCCGGAGAAGCCGACCACCACAG
MLH1_ex19 59 GCCTCCTAAACATTTCACAGAAGA
MLH1_ex19 39 TGGAAATATCCTGCAGCTTGCTAA
DOI: 10.1371/journal.pmed.0030431.t002
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bp into intron 21. The 52 bp section is deﬁned by differences
between CFH and CFHL1 sequence (Figure 4A). Screening of
other family members using primers spanning the breakpoint
and designed to anneal to both CFH and CFHL1 (Figure 4B)
conﬁrmed the breakpoint. Sequence of this region (Figure
4C) shows a switch from heterozygosity at CFH/CFHL1 unique
bases to CFHL1 sequence in III:3 (unaffected carrier) and III:6
(affected) compared with III:1 (unaffected), III:7 (unaffected),
and a normal unrelated control.
CFH Dosage Analysis by Quantitative Fluorescent PCR and
MLPA
CFH dosage quotients showed an apparent heterozygous
‘‘deletion’’ of CFH exons 22 and 23 in II:8 (unaffected carrier),
III:3 (unaffected carrier), III:6 (affected), and IV:1 (affected).
There was no evidence of a ‘‘deletion’’ in III:1 and III:7 (both
unaffected) (Figure 7).
In a panel of 80 patients with aHUS, three further
individuals were identiﬁed by MLPA as having a deletion of
CFH exons 22 and 23. In all three, factor H levels were normal
and CFH gDNA sequencing had shown normal wild-type
sequence, but presence of a hybrid CFH/CFHL1 gene was
conﬁrmed by CFH cDNA sequencing. This showed the same
changes identiﬁed in III:3 and III:6.
In a panel of 100 normal control individuals, MLPA showed
no evidence of a deletion of CFH exons 22 and 23.
Southern Blot
In III:3 (unaffected carrier) and III:6 (affected) a Southern
blot with HindIII showing an additional 8.6 kb band (the band
at ‘‘B’’ in Figure 6B). This additional band is derived from the
hybrid CFH/CFHL1 gene as shown in Figure 6A.
Discussion
In this study we have provided conclusive evidence that
LCR nonhomologous recombination in the RCA cluster of
genes has resulted in the formation of a hybrid CFH/CFHL1
gene that predisposes to the development of aHUS. The
protein product of the hybrid gene is identical to the factor H
mutant c.3572C.T, S1191L/c.3590T.C, V1197A which we
have shown arises by gene conversion in aHUS [10]. We have
previously shown that this mutant is functionally signiﬁcant,
in that binding to C3b is impaired. The hypothesis for the
existence of a hybrid CFH/CFHL1 gene in the family described
in this manuscript was based on two observations. First, we
knew from our original linkage study [1] that the affected
individuals in this family mapped to the RCA cluster at
position 1q32. Moreover, in this family there was a strong
history of disease recurrence following kidney transplanta-
tion, suggesting that a soluble circulating complement
regulator was responsible. Second, our recent observation
that LCRs in the RCA cluster predisposed to gene conversion
events suggested that LCR nonhomologous recombination
Figure 5. MLPA Binding Sites Used to Identify Deletions of CFH Exons 22
and 23
The hybridisation sequence for the 59 and 39 probes are shown by red
and blue, respectively. The genomic sequence of CFH is shown aligned
above CFHL1.
DOI: 10.1371/journal.pmed.0030431.g005
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Hybrid Complement Gene and Atypical HUSFigure 6. Southern Blot Evidence of Genomic Rearrangement
(A) A Southern blot using a 1.1 kb probe overlying CFH exon 21 and CFHL1 exon 4 hybridised to HindIII-digested DNA (sites shown as arrows) will result
in fragments of 11.2 kb from CFH, 1.4 kb from CFHL1, and 8.6 kb from a CFH/CFHL1 hybrid gene. The site of the 1.1 kb probe is indicated above.
(B) Southern blot showing an additional 8.6 kb band (indicated by B) in lanes 2 and 3, which represent III:3 (unaffected carrier) and III:6 (affected)
compared to lanes 1, 4, and 5, which represent III:1 (unaffected) and individuals with homozygous deletion of CFHL1. Bands at A and C represent
fragments of 11.2 kb from CFH and 1.4 kb from CFHL1, respectively. A size ladder is shown to the right with heavy arrows indicating the expected sizes.
DOI: 10.1371/journal.pmed.0030431.g006
Table 3. Complement Levels
Family Member Identifier C3 (0.68–1.80 g/l) C4 (0.18–0.60 g/l) Factor H (0.35–0.59 g/l)
III:1 1.60 0.29 0.75
III.3 0.69 0.19 0.53
III:6 0.55 0.22 0.53
III:7 1.41 0.30 0.58
IV:1 1.06 0.20 0.68
DOI: 10.1371/journal.pmed.0030431.t003
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Hybrid Complement Gene and Atypical HUSmight also be occurring. In support of this was the
observation that the presence of factor H-related protein 1
(encoded by CFHL1) in the serum of normal controls is
polymorphic, with 4.4% of healthy blood donors having
complete deﬁciency [12]. We hypothesised that the crossover
responsible for deletion of CFHL1 could also potentially
result in formation of a CFH/CFHL1 hybrid gene. The
evidence presented here strongly supports this hypothesis.
Moreover, we have evidence from three other unrelated
aHUS patients that the phenomenon is not unique to this
family. Renal transplantation in patients with a CFH mutation
is associated with an 80% risk of the graft being lost to
recurrent disease within two years of transplantation [16]. It
is currently recommended that all patients undergo CFH
genotyping prior to transplantation. However, the hybrid
CFH/CFHL1 gene described here would not be picked up by
genomic sequencing using CFH-speciﬁc primers. We would,
therefore, now recommend that all patients be screened also
with CFH MLPA.
Could the results of this study have implications for other
complement-related diseases? It has been established in
several independent cohorts that CFH alleles act as a
susceptibility factor for age-related macular degeneration
[17–20] and type II membranoproliferative glomeruloneph-
ritis [21]. It would be fascinating to test the hypothesis that
copy number of CFHL1 and CFHL3 acts as a susceptibility
factor for such diseases. It is tempting to speculate that such
an effect might be mediated by an interaction between factor
H and the factor H-related proteins.
Supporting Information
Accession Numbers
Online Mendelian Inheritance in Man (http://www.ncbi.nlm.nih.gov/
entrez/query.fcgi?db¼OMIM) accession numbers for the genes and
conditions discussed in this article are aHUS (235400), CFH (134370),
CFHL1 (134371), CFHL2 (600889), CFHL3 (605336), CFHL4 (OMIM
605337), and CFHL5 (OMIM 608593). The GenBank (http://www.ncbi.
nlm.nih.gov/) accession numbers for other genes are MSH2 exon 1
(NM_000251) and MLH1 exon 19 (NM_000249).
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Editors’ Summary
Background. Atypical hemolytic uremic (aHUS) syndrome is a rare,
chronic disease that can run in families. People with the condition are
prone to developing kidney failure and high blood pressure, and are
likely to have a shorter life span than healthy people. Previous work
done by a group of researchers in Newcastle-on-Tyne, UK looked at the
genetic underpinnings of aHUS in three families suffering from the
condition. They found a region of the genome that was linked with the
disease in all three families. That region was known to contain a gene
for a protein called ‘‘factor H,’’ as well as a number of other genes for
proteins that are involved in the same pathway as factor H in
controlling an ancient defence system called complement. This system
helps antibodies to kill invaders by marking any cell that is not
protected by proteins such as factor H. Our own cells would be under
constant threat without protective proteins such as factor H. Later
studies found simple genetic mutations in people with aHUS, in the
genes coding for factor H. However, other work suggested that in
some families with aHUS, simple genetic mutations might not be the
cause; instead more complicated rearrangements of the genome might
occur which would then result in an abnormal factor H that
incorporated part of the gene for another protective protein called
factor H related protein 1.
Why Was This Study Done? The researchers knew that it was important
to understand the exact genetic mutations linked with aHUS in different
families. This was because the exact type of mutation would help them
predict whether a kidney transplant is likely to be successful in treating
an individual with aHUS who has developed kidney failure. In people
with mutations affecting proteins produced by the kidney, a kidney
transplant would be likely to work; but in people with mutations
affecting factor H, which is produced by the liver, the disease would
probably recur after a kidney transplant.
What Did the Researchers Do and Find? In this study, the researchers
went back to one of the three families with aHUS they had previously
studied. The researchers had shown before that in this family, the disease
was linked with the genome region containing factor H, but no precise
mutation in that region had been found. This time, the researchers
screened the genome of the family members and looked in particular for
a specific rearrangement of the genome that they suspected might be
involved. They found that the genomes in this family had been shuffled in
the factor H region, resulting in an abnormal version of factor H being
produced.
What Do These Findings Mean? The mutation these researchers
identified is likely to result in development of aHUS that does not get
better after a kidney transplant, because the abnormal factor H would still
be produced in the liver after a transplant had been done. Therefore, the
researchers suggest that patients with aHUS be checked for this particular
mutation before it is decided whether to go ahead with a transplant.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0030431.
  US National Institutes of Health Office of Rare Diseases information
about atypical hemolytic uremic syndrome
  The Online Mendelian Inheritance in Man (OMIM) contains an entry on
hemolytic uremic syndrome. OMIM is a database of human genes and
genetic disorders developed by the US National Center for Biotech-
nology Information
  The US National Kidney and Urologic Diseases has a page about
hemolytic uremic syndrome
  The Wikipedia has a page about HUS (note that Wikipedia is a free
online encyclopedia that anyone can edit)
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